insulin icodec/semaglutide 🚨 A new era in therapy! For the first time, a once-weekly basal insulin — Insulin Icodec (Awiqli®) has received FDA approval, potentially transforming the way we manage Type 2 Diabetes First Once-Weekly Basal Insulin Approved

Journal of Biomaterials Science Polymer Edition

And the predictable pharmacokinetic profile that your prescriber relied on when setting your dose gets disrupted

One study found that losing just 10% of your body weight can lead to a 2.2% drop in bone mineral density in the hips and spine (PMC)

f-g , Single-cell clones were established from the polyclonal population, and GGT activity (f) (n = 3 technical replicates from 2 independent experiments) and cell numbers (g) (n = 6 technical replicates for Control or n = 4 technical replicates for Cys 2 -free + GSH from 2 independent experiments) for cells grown in control (208 M cystine

This indication affects about 22 million people in the U.S